Inhibiting the system xC - /glutathione axis selectively targets cancers with mutant-p53 accumulation

Nature Communications

Volumn 8, Issue , 2017, Pages

  Liu, David S ^a,b   Duong, Cuong P ^a   Haupt, Sue ^a   Montgomery, Karen G ^a   House, Colin M ^a   Azar, Walid J ^a   Pearson, Helen B ^a,b,f   Fisher, Oliver M ^c   Read, Matthew ^a,b   Guerra, Glen R ^a,b   Haupt, Ygal ^a,b   Cullinane, Carleen ^a,b   Wiman, Klas G ^d   Abrahmsen, Lars ^e   Phillips, Wayne A ^a,b   Clemons, Nicholas J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c St Vincent's Centre for Applied Medical Research   (Australia)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Aprea AB   (Sweden)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; APR 246; ENZYME ACTIVATOR; GLUTATHIONE; PROTEIN P53; SLC7A11 PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; AMINO ACID TRANSPORTER; NFE2L2 PROTEIN, HUMAN; QUINUCLIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SLC7A11 PROTEIN, HUMAN;

ACCUMULATION; ANTAGONISM; ANTIOXIDANT; APOPTOSIS; BIOMARKER; CANCER; CELL ORGANELLE; CELLS AND CELL COMPONENTS; GENE EXPRESSION; INHIBITION; MUTATION; PROTEIN; VULNERABILITY;

APOPTOSIS; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN STABILITY; SENSITIZATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; PHYSIOLOGICAL STRESS; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; APOPTOSIS; CELL LINE, TUMOR; GLUTATHIONE; HUMANS; LIPID PEROXIDATION; MODELS, BIOLOGICAL; MUTATION; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; QUINUCLIDINES; REACTIVE OXYGEN SPECIES; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85016394935     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14844     Document Type: Article

References (45)

1. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2-8 (2013).
2. Bykov, V. J. & Wiman, K. G. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 588, 2622-2627 (2014).
3. Liu, D. S. et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut 64, 1506-1516 (2015).
4. Mohell, N. et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 6, e1794 (2015).
5. Peng, X. et al APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 4, e881 (2013).
6. Kalo, E. et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J. Cell Sci. 125, 5578-5586 (2012).
7. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591 (2009).
8. Balendiran, G. K., Dabur, R. & Fraser, D. The role ofglutathione in cancer. Cell Biochem. Funct. 22, 343-352 (2004).
9. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
10. Lu, S. C. Regulation of glutathione synthesis. Mol Aspects Med. 30, 42-59 (2009).
11. Bridges, R. J., Natale, N. R. & Patel, S. A. System xT cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br. J. Pharmacol. 165, 20-34 (2012).
12. Reinhold, W. C. et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499-3511 (2012).
13. Reinhold, W. C., Sunshine, M., Varma, S., Doroshow, J. H. & Pommier, Y. Using CellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60. Clin. Cancer Res. 21, 3841-3852 (2015).
14. Lewerenz, J. et al. The cystine/glutamate antiporter system x~ in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18, 522-555 (2013).
15. Sasaki, H. et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277, 44765-44771 (2002).
16. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
17. Tessoulin, B. et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 124, 1626-1636 (2014).
18. Lambert, J. M. et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376-388 (2009).
19. Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237-248 (2008).
20. Loscalzo, J. Membrane redox state and apoptosis: death by peroxide. Cell Metab. 8, 182-183 (2008).
21. Bykov, V. J., Lambert, J. M., Hainaut, P. & Wiman, K. G. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 8, 2509-2517 (2009).
22. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57-62 (2015).
23. Aryee, D. N. et al. Variability in functional p53 reactivation by PRIMA-l(Met)/ APR-246 in Ewing sarcoma. Br. J. Cancer. 109, 2696-2704 (2013).
24. Grellety, T. et al. PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer 15, 684 (2015).
25. Bhutia, Y. D., Babu, E., Ramachandran, S. & Ganapathy, V. Amino acid transporters in cancer and their relevance to 'glutamine addiction': novel targets for the design of a new class of anticancer drugs. Cancer. Res. 75, 1782-1788 (2015).
26. Saha, M. N., Abdi, J., Yang, Y. & Chang, H. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget 7, 7149-7160 (2016).
27. Chorley, B. N. et al. Identification of novel NRF2-regulated genes by ChlP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 40, 7416-7429 (2012).
28. Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system x~ and thereby promotes tumor growth. Cancer Cell 19, 387-400 (2011).
29. La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587-596 (2011).
30. Oren, M. & Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107 (2010).
31. Walerych, D. et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat. Cell Biol. 18, 897-909 (2016).
32. Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
33. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014).
34. Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014).
35. Deneberg, S. et al. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 6, e447 (2016).
36. Shitara, K. et al. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Gastric Cancer 20, 341-349 (2017).
37. Lehmann, S. et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 30, 3633-3639 (2012).
38. Clemons, N. J. et al. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig. Dis. Sci. 59, 78-88 (2014).
39. Blandino, G., Levine, A. J. & Oren, M. Mutant p53 gain offunction: differential effects ofdifferent p53 mutants on resistance ofcultured cells to chemotherapy. Oncogene 18, 477-485 (1999).
40. Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 5, 1704-1713 (2013).
41. Waterhouse, N. J. & Trapani, J. A. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ. 10, 853-855 (2003).
42. Patel, S. A., Warren, B. A., Rhoderick, J. F. & Bridges, R. J. Differentiation of substrate and non-substrate inhibitors of transport system x-: an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46, 273-284 (2004).
43. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
44. Read, M. et al. Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Ann. Surg. Oncol. 23, 305-311 (2016).
45. Rotblat, B., Grunewald, T. G., Leprivier, G., Melino, G. & Knight, R. A. Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget 4, 2577-2590 (2013).